DEF 14A: Kiniksa Pharmaceuticals Proposes Redomiciliation to the United Kingdom, Announces Annual and Special Meetings

Kiniksa Pharmaceuticals is seeking shareholder approval to change its place of incorporation from Bermuda to the United Kingdom, alongside routine annual meeting matters.

Summary

• Kiniksa Pharmaceuticals, Ltd. is holding its 2024 Annual Meeting of Shareholders on June 5, 2024, virtually.
• A Special Court-Ordered Meeting will follow immediately after the Annual Meeting to vote on a proposal to change the company's place of incorporation from Bermuda to the United Kingdom.
• The redomiciliation involves creating a new holding company in England and Wales.
• Shareholders as of April 15, 2024, are entitled to vote.
• The board of directors recommends voting for the election of directors, the appointment of PricewaterhouseCoopers LLP as auditor, and the approval of executive compensation.
• The board also recommends voting for the Scheme of Arrangement to facilitate the redomiciliation and for the adjournment of the Redomiciliation Meeting if necessary to solicit additional proxies.

Sentiment

Score: 7

Explanation: The document is largely procedural, outlining the steps for a corporate action. The sentiment is neutral to slightly positive as the company is taking steps to optimize its structure.

Positives

• The U.K. offers a stable long-term legal and regulatory environment.
• The U.K. possesses robust legal, accounting and financial industries.
• The regulatory environment in the U.K. is broadly favorable for the biopharmaceutical industry.
• The redomiciliation will provide a continuity of legal rights for shareholders on substantially the same grounds as they enjoy in Bermuda.
• The redomiciliation is not anticipated to have any material impact on Kiniksa's effective tax rate.

Negatives

• Shareholder rights will change due to differences between Bermuda law and English law.
• The redomiciliation will result in additional direct and indirect costs, even if it is not completed.
• Increased shareholder voting requirements in the U.K. will reduce flexibility relating to the ability to issue new shares.
• A future transfer of New Kiniksa Shares outside of DTC may be subject to U.K. stamp taxes.

Risks

• The market for Class A Ordinary Shares may differ from the market for the Class A Shares.
• There are no assurances with respect to our effective tax rate following the Redomiciliation.
• The company may choose to abandon or delay the Redomiciliation.
• The company will incur certain legal, accounting, consulting and administrative costs whether or not the Redomiciliation is completed.

Future Outlook

The company expects to complete the redomiciliation on or about June 27, 2024, assuming shareholder and court approvals are obtained and other conditions are satisfied.

Management Comments

• Sanj K. Patel, Chief Executive Officer and Chairman of the Board, urges shareholders to vote and submit their proxies promptly.
• Management believes that moving the principal holding company of the group from Bermuda to a country with more expansive tax treaties globally would likely be in the best interests of our shareholders, employees and other stakeholders in the longer-term, and we believe that moving the place of incorporation and tax residence of the groups principal holding company to the U.K. in this manner is the best available option.

Industry Context

Many companies consider redomiciliation to optimize their tax structure, regulatory environment, and access to international markets. The U.K. is often viewed as a stable and business-friendly jurisdiction.

Comparison to Industry Standards

• Several pharmaceutical companies have redomiciled to jurisdictions perceived as more favorable for tax or regulatory reasons.
• For example, Shire plc redomiciled from the U.K. to Ireland in 2008 to take advantage of lower corporate tax rates.
• Similarly, Jazz Pharmaceuticals redomiciled from Ireland to the U.K. in 2021.
• These moves often involve complex legal and financial considerations, including shareholder approval and potential tax implications.

Stakeholder Impact

• Shareholders will be impacted by the change in the company's domicile and the governing laws.
• Employees may see no immediate changes to their day-to-day operations.
• The company anticipates no material impact on its ability to access capital markets.

Next Steps

• Shareholders need to vote on the proposals.
• The company will seek court approval for the Scheme of Arrangement.
• The company will file the court order with the Bermuda Registrar of Companies to effect the redomiciliation.

Key Dates

Keywords

Redomiciliation, Proxy statement, Annual Meeting, Shareholders, Kiniksa, Bermuda, United Kingdom, Scheme of Arrangement, Directors, Vote